John Ford, Enterprise Therapeutics CEO
January 29, 2024 04:00 AM EST
Financing

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

Katherine Lewin

News Reporter

En­ter­prise Ther­a­peu­tics closed a £26 mil­lion Se­ries B round to fund a Phase IIa tri­al of its cys­tic fi­bro­sis drug, which aims to sig­nif­i­cant­ly im­prove …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times